The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
Official Title: Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Study ID: NCT00753545
Brief Summary: The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Research Site, Berkeley, California, United States
Research Site, Indianapolis, Indiana, United States
Research Site, Boston, Massachusetts, United States
Research Site, Boston, Massachusetts, United States
Research Site, Providence, Rhode Island, United States
Research Site, East Bentleigh, , Australia
Research Site, Melbourne, , Australia
Research Site, Randwick, , Australia
Research Site, South Brisbane, , Australia
Research Site, Innsbruck, , Austria
Research Site, Wein, , Austria
Research Site, Wien, , Austria
Research Site, Brussels, , Belgium
Research Site, Leuven, , Belgium
Research Site, Vancouver, British Columbia, Canada
Research Site, Toronto, Ontario, Canada
Research Site, Sherbrooke, Quebec, Canada
Research Site, Quebec, , Canada
Research Site, Brno, , Czechia
Research Site, Olomouc, , Czechia
Research Site, Praha 10, , Czechia
Research Site, Tallinn, , Estonia
Research Site, Tartu, , Estonia
Research Site, Bordeaux, , France
Research Site, Caen Cedex, , France
Research Site, Lyon Cedex 08, , France
Research Site, Nantes, , France
Research Site, Paris, , France
Research Site, Paris, , France
Research Site, Reims Cedex, , France
Research Site, Essen, , Germany
Research Site, Freiburg, , Germany
Research Site, Göttingen, , Germany
Research Site, Hannover, , Germany
Research Site, Kiel, , Germany
Research Site, Marburg, , Germany
Research Site, München, , Germany
Research Site, Ulm, , Germany
Research Site, Wiesbaden, , Germany
Research Site, Jerusalem, , Israel
Research Site, Jerusalem, , Israel
Research Site, Ramat Gan, , Israel
Research Site, Tel-Aviv, , Israel
Research Site, Zerifin, , Israel
Research Site, Amsterdam, , Netherlands
Research Site, Amsterdam, , Netherlands
Research Site, Grzepnica, , Poland
Research Site, Lublin, , Poland
Research Site, Poznan, , Poland
Research Site, Poznan, , Poland
Research Site, Poznań, , Poland
Research Site, Warszawa, , Poland
Research Site, Cluj-Napoca, , Romania
Research Site, Iasi, , Romania
Research Site, Suceava, , Romania
Research Site, Barnaul, , Russian Federation
Research Site, Ekaterinburg, , Russian Federation
Research Site, Obninsk, , Russian Federation
Research Site, Orenburg, , Russian Federation
Research Site, Perm, , Russian Federation
Research Site, Pyatigorsk, , Russian Federation
Research Site, Saint-Petersburg, , Russian Federation
Research Site, St. Petersburg, , Russian Federation
Research Site, Voronezh, , Russian Federation
Research Site, Córdoba, , Spain
Research Site, Madrid, , Spain
Research Site, Madrid, , Spain
Research Site, Madrid, , Spain
Research Site, Valencia, , Spain
Research Site, Donetsk, , Ukraine
Research Site, Kyiv, , Ukraine
Research Site, Ternopil, , Ukraine
Research Site, Uzhhorod, , Ukraine
Research Site, Edinburgh, , United Kingdom
Research Site, London, , United Kingdom
Research Site, London, , United Kingdom
Research Site, Manchester, , United Kingdom
Research Site, Sutton, , United Kingdom
Research Site, Wirral, , United Kingdom
Name: Mika Sovak, BSc, MBCHB, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Prof Jonathan A Lederman
Affiliation: University College, London
Role: PRINCIPAL_INVESTIGATOR